Feldan Therapeutics is a biotechnology company that introduced the Feldan Shuttle, a peptide-based platform that allows safe and efficient delivery of proteins, peptides and small molecules inside cells. This technology has the potential to help treat many diseases by targeting intracellular pathways. Feldan is focused on bringing its two therapeutic applications (topical product for BCC/Gorlin patients and inhaled CRISPR-based therapy for Cystic Fibrosis) to the clinic. The company is looking to raise its Series B round of financing mid-2021 to finance Phase I/II clinical trial of our first-to-human indication (Gorlin syndrome) as well as the pre-clinical phase of our Cystic Fibrosis indication.

Presenter: Francois-Thomas Michaud, Chief Executive Officer

Specific Biologics is a discovery stage company developing platform gene editing technologies as therapeutics to treat or cure disease through precision gene editing. Our gene editor Dualase is designed to overcome two problems with current gene editor – random DNA insertions / deletions and low frequency repair. Unlike other technologies, Dualase cuts DNA in two spots and leaves non-compatible DNA ends. These ends create precise deletions to disrupt DNA or increase rates of repair to correct DNA. We are raising $2.7 million CAD to advance our programs in cystic fibrosis and oncology in preclinical animal models and further develop the platform.

Presenter: Brent Stead, CEO